Agilent receives european ivdr certification for companion diagnostic assay in gastric or gastroesophageal junction (gej) adenocarcinoma

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced its pd-l1 ihc 22c3 pharmdx (code sk006) assay has received european ivdr certification for the use as a companion diagnostic (cdx) to aid in the identification of gastric or gastroesophageal junction (gej) adenocarcinoma patients who may be eligible for treatment with keytruda® (pembrolizumab)1. pd-l1 ihc 22c3 pharmdx (code sk006) is approved for exclusive use with the agilent autostainer link 48 advanced.
A Ratings Summary
A Quant Ranking